Anti-tumor polypeptide with double effects and application thereof

An anti-tumor and anti-tumor technology, applied in the field of biomedicine, can solve the problems of poor prognosis of patients, achieve the effects of short research and development cycle, inhibit tumor cell proliferation, and increase permeability

Active Publication Date: 2020-04-17
HARBIN MEDICAL UNIVERSITY
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Clinical studies have found that a variety of digestive system tumors, including pancreatic cancer, gastric cancer, liver cancer, and cholangiocarcinoma, highly express NRP-1, and its expression level is positively correlated with clinicopathological features. Patients with high expression of NRP-1 have a poor prognosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-tumor polypeptide with double effects and application thereof
  • Anti-tumor polypeptide with double effects and application thereof
  • Anti-tumor polypeptide with double effects and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] The preparation of embodiment 1TMD6-D polypeptide

[0066] Proceed as follows:

[0067] 1. Resin swelling: Weigh 0.6g of CTC resin with a substitution degree of 1.0mmol / g, place it in a reaction tube, add DCM (15ml / g), and shake for 30min.

[0068] 2. Deprotection: Remove DCM, add 20% piperidine DMF solution (15ml / g), shake for 5min, remove piperidine solution, add fresh 20% piperidine DMF solution (15ml / g), shake for 15min.

[0069] 3. Detection: Take out the piperidine solution, take a small amount of resin (about 20 resins), wash it three times with ethanol, add one drop of ninhydrin, KCN, and phenol solution, heat (105-110°C) for 5 minutes, and it turns blue .

[0070] Four. Washing for the first time: wash twice with DMF solution (10ml / g), then wash twice with methanol (10ml / g), and finally wash twice with DMF solution (10ml / g).

[0071] 5. Condensation: Three-fold excess of protected amino acids and three-fold excess of HBTU were dissolved with as little DMF as...

Embodiment 2

[0079] Example 2 Detection of Permeability of Vascular Endothelial Cells in Vitro

[0080] Human umbilical vein endothelial cells (HUVECs) or siRNA-transfected HUVECs (1×10 5 ) were inoculated in 12-well transwell chambers (0.4 micron pore size), and cultured in DMEM (Dulbecco's modified Eagle's medium) medium containing 10% fetal bovine serum (FBS). at 37°C and 5% CO 2 After 48-96 hours of incubation under conditions, when HUVECs formed a mature monolayer of cells and covered the bottom membrane of the upper chamber, the culture solution was aspirated, and serum-free DMEM culture solution was added, and VEGF recombinant protein (50ng / ml) was added, Or eight kinds of polypeptides (the concentration is 25nM), or different concentrations of TMD6-D polypeptides. After incubation for 30 minutes, 50 mg of fluorescein isothiocyanate (FITC)-conjugated dextran (molecular weight 40 kDa, 1 mg / mL) was added to the upper chamber. After continuing to incubate for 30 minutes, the lower c...

Embodiment 3

[0085] Example 3 Detection of tumor tissue permeability in vivo

[0086] Female BALB / c nude mice (6-8 weeks old) received subcutaneous injection of human pancreatic cancer BxPC-3 cells (2×10 6 ), to establish subcutaneous pancreatic cancer tumors. Three weeks later, when the tumor had grown to a diameter of about 1 cm, the animals were divided into three groups (3 nude mice in each group). Control group: inject 1 mg of Evans Blue (Evans Blue) (dissolved in 200 μl of PBS) through the tail vein; positive control group: inject a mixture of 1 mg of Evans Blue and VEGF recombinant protein (400 ng) through the tail vein (dissolved in 200 μl of PBS); TMD6-D group: a mixture of 1 mg of Evans blue and TMD6-D polypeptide (500 μg) was injected via the tail vein (dissolved in 200 μl of PBS). Thirty minutes later, anesthesia was induced by intraperitoneal injection of a mixture of ketamine and xylazine, and circulatory lavage with 1% BSA (bovine serum albumin, bovineserum albumin) (disso...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an anti-tumor polypeptide with double effects and an application thereof. The anti-tumor polypeptide with double effects has an amino acid sequence shown as SEQ ID NO.4. The polypeptide provided by the invention can specifically target NRP-1 molecules expressed on endothelial cells and tumor cells, improve the permeability of vascular endothelial cells and increase the permeability of tumor tissues, thereby improving the capacity of a drug penetrating through a vascular barrier and permeating into the tumor tissues. Meanwhile, proliferation of cancer cells can be inhibited and apoptosis of the cancer cells can be promoted by blocking a downstream cell signal path regulated and controlled by NRP-1. The polypeptide disclosed by the invention can be used for treating various solid tumors including pancreatic cancer, and can improve the effect of treating malignant tumors by using drugs, especially using a monoclonal antibody targeted drug.

Description

technical field [0001] The present invention relates to an anti-tumor polypeptide with dual functions and its application in the preparation of anti-tumor drugs, in particular to a polypeptide that targets solid tumor cell membranes and highly expresses NRP-1. The ability to penetrate into tumor tissue, thereby improving the anti-tumor efficacy of monoclonal antibody-targeted drugs; at the same time, it also has the activity of directly inhibiting tumor growth. The invention belongs to the technical field of biomedicine. Background technique [0002] Therapeutic monoclonal antibodies have become a hotspot in the development of new drugs worldwide. Since the first monoclonal antibody drug was launched in 1986 and the first anti-tumor monoclonal antibody drug was launched for the treatment of non-Hodgkin's lymphoma in 1997, nearly a hundred therapeutic monoclonal antibody drugs have been approved for marketing. For the treatment of tumors, autoimmune diseases and inflammator...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08C12N15/11A61K38/10A61K47/42A61P35/00
CPCA61K38/00A61K47/42A61P35/00C07K7/08
Inventor 孙学英李伟东李子一姜宪乔海泉
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap